Health-cultivation Laboratory of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, China.
Academy of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Pharm Biol. 2022 Dec;60(1):2002-2010. doi: 10.1080/13880209.2022.2096075.
Tangnaikang (TNK) is a Chinese herbal formulation that has lipid-lowering effects, but its effect on reducing obesity has not been studied.
To observe the effect of TNK on obesity and explore its effect on gut microbiota of obese rats.
The SHR/NDmcr-cp rats were divided into three groups: (1) 3.24 g/kg TNK (High TNK), (2) 1.62 g/kg TNK (Low TNK), and (3) an untreated control (CON). Wistar-Kyoto rats were used as normal controls (WKY). After 8 weeks of TNK oral administration, body weight, abdominal circumference, triglycerides (TC) and total cholesterol (CHO) were measured. Gut microbiota diversity was studied by 16S rDNA sequencing, and metagenomes analysis was conducted to determine alteration in functional gene expression.
The body weight (496.60 ± 6.0 g vs. 523.40 ± 5.6 g), abdomen circumference (24.00 ± 0.11 cm vs. 24.87 ± 0.25 cm), TC (3.04 ± 0.16 mmol/L vs. 4.97 ± 0.21 mmol/L), CHO (2.42 ± 0.15 mmol/L vs. 2.84 ± 0.09 mmol/L) of rats in the High TNK group were decreased significantly (all < 0.05). TNK administration regulates intestinal flora, up-regulates and down-regulates , which is beneficial to the production of short-chain fatty acids (SCFAs). Metagenomes analysis shows that TNK is closely related to the fatty acid synthesis pathway.
TNK can regulate gut microbiota to reduce obesity, which may be related to fatty acid metabolism. Our research supports the clinical application of TNK preparation and provides a new perspective for the treatment of obesity.
糖乃康（TNK）是一种具有降脂作用的中草药配方，但尚未研究其降低肥胖的作用。
观察 TNK 对肥胖的影响，并探讨其对肥胖大鼠肠道微生物群的影响。
SHR/NDmcr-cp 大鼠分为三组：（1）3.24 g/kg TNK（高 TNK），（2）1.62 g/kg TNK（低 TNK）和（3）未治疗对照组（CON）。Wistar-Kyoto 大鼠作为正常对照（WKY）。口服 TNK 8 周后，测量体重、腹围、甘油三酯（TC）和总胆固醇（CHO）。通过 16S rDNA 测序研究肠道微生物多样性，并进行宏基因组分析以确定功能基因表达的变化。
高 TNK 组大鼠体重（496.60 ± 6.0 g 比 523.40 ± 5.6 g）、腹围（24.00 ± 0.11 cm 比 24.87 ± 0.25 cm）、TC（3.04 ± 0.16 mmol/L 比 4.97 ± 0.21 mmol/L）、CHO（2.42 ± 0.15 mmol/L 比 2.84 ± 0.09 mmol/L）均显著降低（均<0.05）。TNK 给药调节肠道菌群，上调和下调，有利于短链脂肪酸（SCFAs）的产生。宏基因组分析表明，TNK 与脂肪酸合成途径密切相关。
TNK 可调节肠道菌群减少肥胖，这可能与脂肪酸代谢有关。我们的研究支持 TNK 制剂的临床应用，并为肥胖的治疗提供了新视角。
